Summary
Cannot be validated against the supplied JYLAMVO prescribing information: the prompt provides only a list of claims without the AI-generated narrative/response text and without any explicit label-mapped dosing/interaction details. Multiple renal/toxicity/monitoring and interaction concepts are asserted, but the supplied label excerpts do not include the specific renal-clearance, dose-adjustment-by-eGFR/creatinine, holding during AKI/dehydration, or interaction specificity needed to confirm these claims.
Category Scores
Accurate Statements
Methotrexate can cause renal toxicity, including irreversible acute renal failure.
Label 5.8 Renal Toxicity: “Methotrexate can cause renal toxicity, including irreversible acute renal failure…”
Methotrexate suppresses hematopoiesis and can cause severe and life-threatening pancytopenia and other cytopenias.
Label 5.3 Myelosuppression: “Methotrexate suppresses hematopoiesis and can cause severe and life-threatening pancytopenia, anemia, leukopenia, neutropenia, and thrombocytopenia.”
Diarrhea, vomiting, nausea, and stomatitis are among gastrointestinal toxicities reported with methotrexate for non-neoplastic diseases (up to 10%).
Label 5.4 Gastrointestinal Toxicity: “Diarrhea, vomiting, nausea, and stomatitis occurred in up to 10% of patients…”
Methotrexate can cause pulmonary toxicity including interstitial pneumonitis and irreversible or fatal cases.
Label 5.6 Pulmonary Toxicity: “Pulmonary toxicity, including acute or chronic interstitial pneumonitis and irreversible or fatal cases, can occur…”
Methotrexate can cause severe hepatotoxicity including fibrosis, cirrhosis, and fatal liver failure.
Label 5.5 Hepatotoxicity: “Methotrexate can cause severe and potentially irreversible hepatotoxicity, including fibrosis, cirrhosis, and fatal liver failure…”
Patients treated with methotrexate are at increased risk for life-threatening or fatal bacterial, fungal, or viral infections.
Label 5.11 Serious Infections: “Patients treated with methotrexate are at increased risk for developing life-threatening or fatal bacterial, fungal, or viral infections…”
Methotrexate can cause severe acute and chronic neurotoxicity that can be progressive, irreversible, and fatal.
Label 5.12 Neurotoxicity: “Methotrexate can cause severe acute and chronic neurotoxicity, which can be progressive, irreversible, and fatal…”
Unsupported Statements
Methotrexate is cleared by the kidneys.
Supplied label excerpts include renal toxicity (5.8) but do not state renal clearance as a mechanism.
Kidney disease can increase methotrexate drug exposure.
Label excerpts do not describe exposure increases due to kidney disease.
Increased methotrexate exposure raises the risk of serious side effects.
The provided label excerpts do not establish a direct exposure-risk relationship.
When kidney function is reduced, clinicians generally adjust the dose.
No renal dose-adjustment guidance is provided in the supplied label excerpts.
When kidney impairment is more severe, clinicians may avoid methotrexate altogether.
No statement in the supplied label excerpts supports avoiding methotrexate based on severity of renal impairment.
Safe methotrexate dosing depends on how low kidney function is.
No dosing-by-kidney-function thresholds are provided in the supplied excerpts.
Kidney function is often estimated using creatinine-based calculations.
No guidance on creatinine/eGFR estimation is included in the supplied excerpts.
The key factor is a person’s current kidney function, not just the diagnosis name.
No such principle is stated in the supplied label excerpts.
Dose adjustments for methotrexate depend on kidney function.
No dosing adjustment criteria based on kidney function are included in the supplied label excerpts.
As kidney function declines, methotrexate doses often need to be reduced.
No such trend statement is supported by the supplied label excerpts.
As kidney function declines, methotrexate may need to be stopped to prevent toxicity.
The supplied excerpts include withholding/dose reduce/discontinue language in the context of myelosuppression and severe GI toxicity, but not a kidney-function-driven stopping rule.
Specific methotrexate dose adjustment varies by protocol and methotrexate regimen.
No protocol/regimen-specific renal dose adjustment details are present in the supplied excerpts.
Methotrexate regimens can include low-dose weekly use for inflammatory/autoimmune conditions.
While non-neoplastic indications are listed, the supplied excerpts do not include dosing schedules (e.g., low-dose weekly).
Methotrexate regimens can include higher-dose oncology regimens.
The supplied excerpts do not provide dosing ranges/schedules distinguishing oncology regimens.
Methotrexate dose adjustment should be determined by the prescribing clinician using recent lab results.
Label excerpt states obtain blood counts baseline/periodically/as clinically indicated, but does not give kidney-specific dose adjustment instructions by recent labs.
Higher methotrexate exposure increases the risk of mouth sores and ulcers (stomatitis).
Label supports stomatitis occurrence as GI toxicity, but does not link it to exposure increases.
Higher methotrexate exposure increases the risk of low blood counts (bone marrow suppression).
Label supports myelosuppression, but does not link to exposure.
Low blood counts from methotrexate can include an infection risk.
Label supports increased risk of serious infections, but does not specify that infection risk is due to low counts.
Higher methotrexate exposure increases the risk of liver enzyme abnormalities.
Label excerpt states hepatotoxicity including severe irreversible outcomes but does not mention liver enzyme abnormalities or exposure linkage.
Methotrexate can cause nausea, vomiting, and diarrhea.
Partially supported by GI toxicity excerpt, but the claim is broad without specifying non-neoplastic-disease context; still generally consistent. Marking as unsupported due to missing label context details.
Methotrexate-related lung inflammation is rare but serious.
Label excerpt supports pulmonary toxicity can occur with irreversible/fatal cases but does not state rarity.
Kidney-related harm can occur in some circumstances with methotrexate, creating a cycle of worsening risk.
No causal cycle description is present in supplied label excerpts.
Methotrexate is commonly avoided when kidney function is significantly impaired.
No statement about common avoidance based on kidney function severity is included.
The reason for avoiding methotrexate in significant kidney impairment is that toxic accumulation risk becomes too high.
No explanation of accumulation/avoidance rationale is present in supplied excerpts.
Clinicians may stop or hold methotrexate temporarily during acute kidney injury.
No AKI-specific withholding/holding instruction is provided in supplied excerpts.
Clinicians may stop or hold methotrexate temporarily during dehydration.
No dehydration-specific withholding/holding instruction is provided in supplied excerpts.
Acute kidney injury and dehydration can rapidly reduce methotrexate kidney clearance.
Renal clearance mechanism and rapid reduction are not described in the supplied label excerpts.
Risk of methotrexate toxicity rises when kidney clearance drops quickly or becomes unpredictable.
No label support for this clearance-to-toxicity relationship.
Situations that increase the risk of dehydration or impaired perfusion are examples that increase methotrexate risk.
No perfusion/dehydration risk factor guidance is present in supplied excerpts.
Some medicines can increase methotrexate levels.
The label states certain coadministrations may increase methotrexate plasma concentrations, so this is generally consistent, but the claim is too nonspecific without listing; still supported in concept. However, since the statement claims broadly without tying to the label’s listed products, mark as unsupported for audit strictness.
Some medicines can add to kidney stress.
No such statement is in the supplied label excerpts.
Clinicians review the full medication list carefully before and during methotrexate therapy because of interactions that matter for kidney patients.
Label excerpts state drug interactions may increase plasma concentrations and require coadministration caution, but do not mention kidney-patient-specific interaction emphasis.
People with chronic kidney disease on methotrexate typically need more careful monitoring.
No chronic kidney disease-specific monitoring frequency guidance is included.
Monitoring for methotrexate in kidney patients includes repeat kidney function testing.
Supplied excerpt only mentions obtaining blood counts baseline/periodically/as clinically indicated; no kidney-function testing monitoring guidance is provided.
Monitoring frequency depends on how stable kidney function is.
No monitoring frequency guidance tied to kidney-function stability is included.
Before continuing methotrexate in kidney disease, clinicians often base decisions on recent labs and current symptoms.
No kidney-disease-specific continuation decision guidance is included.
Methotrexate dosing decisions may require changing the dose if the person cannot maintain normal hydration.
No hydration-based dose-change guidance is provided.
Methotrexate dosing decisions may require changing the dose after recent hospitalization or acute illness.
No hospitalization/acute illness-specific renal dose adjustment guidance is provided.
Methotrexate dosing decisions may require changing the dose if new medications were started.
The label excerpt indicates interactions may increase methotrexate concentrations, but does not provide dosing-change triggers tied to new meds.
Methotrexate toxicity may be suspected when fever or signs of infection occur.
Label supports increased risk of infections but does not specify fever/signs as a toxicity suspicion trigger.
Methotrexate toxicity may be suspected when shortness of breath or persistent cough occurs.
Label supports pulmonary toxicity but does not connect cough/SOB as suspicion criteria in the supplied excerpts.
Methotrexate toxicity may be suspected when black/tarry stools or vomiting blood occurs.
No GI bleeding symptom list is provided in supplied excerpts.
Methotrexate toxicity may be suspected when severe diarrhea, persistent vomiting, or inability to keep fluids down occurs.
Label supports withholding/discontinuing for severe GI toxicity but does not define these as toxicity-suspicion criteria.
For inflammatory and autoimmune conditions where methotrexate is used, clinicians may consider alternatives that are safer in kidney impairment.
No guidance on alternative selection by kidney impairment is included.
The best alternative to methotrexate depends on the condition being treated / disease severity / level of kidney function.
No alternative therapy selection guidance is present in the supplied excerpts.
Clinicians use the reason for methotrexate use (e.g., rheumatoid arthritis or psoriasis) to decide methotrexate dosing and monitoring.
Indications are listed in label, but the supplied excerpts do not provide dosing/monitoring differences by indication.
Clinicians use the patient’s methotrexate dose and schedule (weekly dose, and route if known) for dosing and monitoring decisions.
Monitoring frequency is discussed generally (baseline/periodically/as clinically indicated) but no scheduling/route-dependent monitoring guidance is included.
Contradictions
Low
AI Statement
Methotrexate is commonly avoided when kidney function is significantly impaired.
Label Reference
No label excerpt provided supports routine avoidance based on kidney impairment severity; therefore not a direct contradiction, but unsupported. No direct contradiction present.
Important Omissions
Label-required contraindications: pregnancy for non-neoplastic diseases and hypersensitivity/anaphylaxis history leading to permanent discontinuation guidance are not discussed in the provided claims.
Importance:
Moderate
Label interaction specifics: the excerpt indicates certain products may increase methotrexate plasma concentrations, but no named drug classes/agents from the label are provided in the claims.
Importance:
Moderate
Label monitoring specificity beyond blood counts: the supplied claims focus on kidney-function testing, but the supplied label excerpt explicitly instructs obtaining baseline and periodic blood counts and withholding/dose reduction/discontinuation for certain toxicities.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple high-stakes assertions are made about renal clearance/exposure, dose adjustment/avoidance during kidney impairment, and monitoring specifics, but these details are not supported by the provided JYLAMVO label excerpts. Such unsupported statements could lead to incorrect dosing/holding decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Renal-clearance/exposure mechanisms and kidney-function-driven dose adjustment/holding/monitoring claims are not supported by the supplied JYLAMVO label excerpts, and several safety statements (e.g., rarity phrasing, toxicity-suspicion symptom triggers) are not substantiated.
Suggested Improvement
Restrict claims to label-supported content from the provided excerpts (renal toxicity; myelosuppression and need for blood count monitoring; GI toxicities incl. stomatitis; hepatotoxicity; pulmonary toxicity; serious infections). For renal-related dosing/holding/monitoring, include only text explicitly present in the label or omit those specifics until the relevant sections are provided.